FULC Stock: Fulcrum Therapeutics, Inc. Stock Price, Analysis & Insights
Get live fulc stock price $11.55, comprehensive Fulcrum Therapeutics, Inc. stock analysis, charts, news, and expert forecast. Real-time fulc stock data and investment insights.
Loading chart...
Company Overview
Fulcrum Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing products for improving the lives of patients with genetically defined diseases in the areas of high unmet medical need in the United States. Its product candidates are losmapimod, a small molecule for the treatment of facioscapulohumeral muscular dystrophy; and FTX-6058, an investigational oral fetal hemoglobin inducer for the treatment of sickle cell disease and other hemoglobinopathies, including beta-thalassemia. The company is also discovering drug targets for the treatments of rare neuromuscular, muscular, central nervous system, and hematologic disorders, as well as cardiomyopathies and pulmonary diseases. Fulcrum Therapeutics, Inc. has research and discovery collaboration agreement with Acceleron Pharma Inc. to identify biological targets to modulate specific pathways associated with a targeted indication within the pulmonary disease space; and has a strategic collaboration and license agreement with MyoKardia, Inc. to discover, develop, and commercialize novel targeted therapies for the treatment of genetic cardiomyopathies. Fulcrum Therapeutics, Inc. was Incorporated in 2015 and is headquartered in Cambridge, Massachusetts.
Company Information
- CEO
- Alexander C. Sapir
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 45
Contact Information
- Website
- https://www.fulcrumtx.com
- Address
- 26 Landsdowne Street
- Country
- US
Investment Analysis & Business Insights
Investment Highlights
✓ Strong presence in the Healthcare sector with established market position
✓ Higher growth potential with elevated volatility (Beta: 3.19)
Business Model & Strategy
Fulcrum Therapeutics, Inc. operates in the Biotechnology industry, focusing on medical services, pharmaceutical development, and healthcare delivery. Under the leadership of CEO Alexander C. Sapir, the company navigates Healthcare sector dynamics while pursuing growth opportunities. The Biotechnology model requires regulatory compliance, research investment, and patient outcomes to maintain competitiveness and drive shareholder value.
Market Position & Competitive Landscape
Fulcrum Therapeutics, Inc. competes in the Biotechnology within the broader Healthcare. With 625.0 million in market capitalization, the company is positioned as a emerging competitor in its sector. The Healthcare is characterized by demographic shifts, regulatory changes, and medical breakthroughs. As a publicly traded company on the NASDAQ Global Market, Fulcrum Therapeutics, Inc. provides investors with liquidity and transparency while subject to regulatory oversight. Investors evaluating Fulcrum Therapeutics, Inc. should consider industry-specific trends, competitive positioning, and Healthcare sector fundamentals.
Important Investment Considerations
- ⚠All investments carry risk, including potential loss of principal for Fulcrum Therapeutics, Inc. shareholders
- ⚠Market volatility can significantly impact stock price, especially for smaller companies
- ⚠Sector-specific risks in Healthcare may affect company performance
- ⚠Past performance does not guarantee future results for Fulcrum Therapeutics, Inc.
- ⚠Investors should consider how Fulcrum Therapeutics, Inc. fits within their overall portfolio allocation
- ⚠Valuation metrics suggest potential, but require fundamental analysis
Market Cap
624.99M
P/E Ratio
-10.13
Beta
3.19
Investment Analysis & Insights
Key Investment Highlights
- Market Position: Healthcare leader with 624.99M market capitalization
- Trading Volume: 2.04M shares traded today
- Price Range: 52-week range of $2.31 - $12.19
- Exchange: Listed on NASDAQ Global Market
Financial Metrics
Market Analysis for Fulcrum Therapeutics, Inc.
Fulcrum Therapeutics, Inc. (FULC) operates in the Biotechnology industry within the Healthcare sector. With a current market capitalization of 624.99M, the company represents a significant player in its market. The stock is currently trading at $11.55 with a positivedaily change of 18.71%.
The company's 45 employee base and presence on the NASDAQ Global Marketexchange position it as a Healthcare sector leader. Investors should consider the stock's P/E ratio of -10.13, beta of 3.19, and 52-week price range from $2.31 to $12.19when evaluating investment opportunities.
Why Invest in Fulcrum Therapeutics, Inc.?
Strengths
- • Established market presence in Healthcare
- • Strong financial metrics and market position
- • Listed on major exchange (NASDAQ Global Market)
- • Experienced leadership under Alexander C. Sapir
Investment Considerations
- • Monitor sector-specific market trends
- • Track quarterly earnings performance
- • Consider market volatility and beta
- • Evaluate long-term growth potential
Related Healthcare Stocks
About Healthcare Sector
The Healthcare sector includes companies that provide medical services, develop pharmaceuticals, manufacture medical devices, and offer health insurance.